rilvegostomig
AstraZeneca
['sclc', 'nsclc']
rilvegostomig showed early signs of tolerability and efficacy in patients with advanced or metastatic pd-l1 positive nsclc following progression on at least 1 prior checkpoint inhibitor. #asco2023 
Oncology news and insights from leading researchers and cancer centers.